A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.
Also called NCT02548585
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 113 participants
- Sponsor
- Registry
-
NCT02548585
-
- Other papers using this trial's data
- Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT02548585. Randomized; quadruple masking; primary purpose treatment. Start 2015-12-09 (actual); primary completion 2017-02-24 (actual). Results posted on 2019-04-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- MEDI0382
- Intervention (Drug)
- Placebo
- Lead sponsor
- MedImmune LLC
Record details
- Record id
cardio:ct-nct02548585- Content hash
4f2ad36e24d839a00d322f4240906409e873dc527e3b207d8eedc75dbb9d2ac8